Bristol Investments vs Accounts Payable Analysis

BMY Stock  USD 53.25  0.70  1.33%   
Bristol Myers financial indicator trend analysis is way more than just evaluating Bristol-Myers Squibb prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bristol-Myers Squibb is a good investment. Please check the relationship between Bristol Myers Investments and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

Investments vs Accounts Payable

Investments vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bristol-Myers Squibb Investments account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Bristol Myers' Investments and Accounts Payable is 0.41. Overlapping area represents the amount of variation of Investments that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Bristol Myers Squibb, assuming nothing else is changed. The correlation between historical values of Bristol Myers' Investments and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Investments of Bristol Myers Squibb are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Investments i.e., Bristol Myers' Investments and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.41
Relationship DirectionPositive 
Relationship StrengthWeak

Investments

Securities or assets acquired for generating income or appreciating in value, not used in daily operations.

Accounts Payable

An accounting item on the balance sheet that represents Bristol Myers obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Bristol-Myers Squibb are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Bristol Myers' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bristol-Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
At this time, Bristol Myers' Selling General Administrative is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 12.21 in 2024, whereas Discontinued Operations is likely to drop slightly above 6 B in 2024.
 2021 2022 2023 2024 (projected)
Gross Profit36.4B36.0B34.3B36.0B
Total Revenue46.4B46.2B45.0B47.3B

Bristol Myers fundamental ratios Correlations

0.980.810.930.890.780.98-0.070.90.990.520.830.760.970.460.990.82-0.160.880.990.70.940.850.960.60.88
0.980.780.920.840.791.0-0.160.940.970.380.880.820.980.520.990.76-0.240.890.990.760.950.890.950.570.91
0.810.780.950.550.690.81-0.10.630.770.640.550.770.810.420.760.520.10.60.830.770.870.670.650.620.73
0.930.920.950.70.80.93-0.070.810.890.520.750.880.950.430.90.66-0.040.730.940.870.970.840.80.660.85
0.890.840.550.70.750.840.130.790.910.410.730.50.820.450.880.9-0.140.820.850.430.760.730.930.620.81
0.780.790.690.80.750.790.280.730.760.190.70.770.840.430.780.64-0.130.530.80.750.790.780.70.850.85
0.981.00.810.930.840.79-0.170.90.980.420.830.820.980.530.990.77-0.210.890.990.760.930.890.950.560.91
-0.07-0.16-0.1-0.070.130.28-0.17-0.12-0.07-0.11-0.07-0.11-0.03-0.61-0.120.170.35-0.45-0.11-0.06-0.05-0.16-0.130.44-0.14
0.90.940.630.810.790.730.9-0.120.870.210.980.780.90.470.920.66-0.320.830.910.690.910.850.870.570.84
0.990.970.770.890.910.760.98-0.070.870.530.80.710.950.460.990.84-0.190.890.980.650.910.830.980.570.86
0.520.380.640.520.410.190.42-0.110.210.530.120.160.380.170.450.490.120.440.480.180.450.180.450.210.35
0.830.880.550.750.730.70.83-0.070.980.80.120.760.840.40.850.6-0.370.740.840.670.870.80.80.580.78
0.760.820.770.880.50.770.82-0.110.780.710.160.760.880.370.760.48-0.290.580.80.970.860.870.620.530.8
0.970.980.810.950.820.840.98-0.030.90.950.380.840.880.410.970.78-0.190.810.980.830.950.90.90.630.89
0.460.520.420.430.450.430.53-0.610.470.460.170.40.370.410.50.21-0.330.690.490.320.410.540.510.290.65
0.990.990.760.90.880.780.99-0.120.920.990.450.850.760.970.50.8-0.220.90.990.690.930.860.970.580.88
0.820.760.520.660.90.640.770.170.660.840.490.60.480.780.210.8-0.070.720.780.450.690.650.860.520.75
-0.16-0.240.1-0.04-0.14-0.13-0.210.35-0.32-0.190.12-0.37-0.29-0.19-0.33-0.22-0.07-0.33-0.18-0.19-0.07-0.32-0.240.15-0.26
0.880.890.60.730.820.530.89-0.450.830.890.440.740.580.810.690.90.72-0.330.870.490.770.780.940.30.81
0.990.990.830.940.850.80.99-0.110.910.980.480.840.80.980.490.990.78-0.180.870.750.960.870.950.610.89
0.70.760.770.870.430.750.76-0.060.690.650.180.670.970.830.320.690.45-0.190.490.750.820.830.550.560.75
0.940.950.870.970.760.790.93-0.050.910.910.450.870.860.950.410.930.69-0.070.770.960.820.850.840.680.86
0.850.890.670.840.730.780.89-0.160.850.830.180.80.870.90.540.860.65-0.320.780.870.830.850.820.530.84
0.960.950.650.80.930.70.95-0.130.870.980.450.80.620.90.510.970.86-0.240.940.950.550.840.820.50.83
0.60.570.620.660.620.850.560.440.570.570.210.580.530.630.290.580.520.150.30.610.560.680.530.50.64
0.880.910.730.850.810.850.91-0.140.840.860.350.780.80.890.650.880.75-0.260.810.890.750.860.840.830.64
Click cells to compare fundamentals

Bristol Myers Account Relationship Matchups

Bristol Myers fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets129.9B118.5B109.3B96.8B95.2B99.9B
Short Long Term Debt Total47.5B51.7B45.6B40.7B41.5B43.5B
Other Current Liab7.9B10.2B10.1B13.1B11.5B12.1B
Total Current Liabilities18.3B19.1B21.9B21.9B22.3B23.4B
Total Stockholder Equity51.6B37.8B35.9B31.1B29.4B15.0B
Property Plant And Equipment Net6.3B6.7B7.0B7.5B8.0B5.2B
Net Debt35.2B37.1B31.6B31.6B30B31.5B
Retained Earnings34.5B21.3B23.8B25.5B28.8B22.0B
Cash12.3B14.5B14.0B9.1B11.5B12.0B
Non Current Assets Total100.6B88.3B76.1B69.5B63.4B66.6B
Non Currrent Assets Other6.6B2.1B1.7B1.0B1.9B2.0B
Cash And Short Term Investments12.3B14.5B14.0B9.1B12.3B12.9B
Net Receivables7.7B8.5B12.5B13.9B15.3B16.0B
Good Will22.5B20.5B20.5B21.1B21.2B22.2B
Common Stock Shares Outstanding1.6B1.7B2.3B2.2B2.1B1.6B
Liabilities And Stockholders Equity129.9B118.5B109.3B96.8B95.2B99.9B
Non Current Liabilities Total59.9B61.5B51.4B43.8B43.4B45.6B
Inventory4.3B2.1B2.1B2.3B2.7B1.9B
Other Current Assets2.0B1.4B1.3B1.6B1.5B1.8B
Other Stockholder Equity18.4B18.1B13.1B6.5B1.9B2.0B
Total Liab78.2B80.6B73.3B65.7B65.7B69.0B
Property Plant And Equipment Gross6.3B5.9B11.0B11.6B12.8B13.5B
Total Current Assets29.4B30.2B33.3B27.3B31.8B33.4B
Accumulated Other Comprehensive Income(1.5B)(1.8B)(1.3B)(1.3B)(1.5B)(1.6B)
Short Term Debt3.5B2.5B5.1B4.4B3.3B3.4B
Intangible Assets64.0B53.2B42.8B36.4B27.5B28.9B
Accounts Payable2.4B2.7B2.9B3.0B3.3B1.9B
Short Term Investments3.0B1.3B3.2B130M816M775.2M
Other Liab15.9B12.3B11.0B7.4B8.5B4.9B
Other Assets4.8B7.3B3.3B2.9B3.3B3.3B
Long Term Debt43.4B48.3B39.6B35.1B36.7B38.5B
Treasury Stock(19.6B)(25.4B)(26.2B)(31.3B)(28.1B)(26.7B)
Property Plant Equipment6.3B5.9B6.0B6.3B7.2B5.8B
Current Deferred Revenue4.5B3.6B3.7B1.3B4.2B4.4B
Net Tangible Assets(34.9B)(36.0B)(28.2B)(25.9B)(23.4B)(22.2B)
Noncontrolling Interest In Consolidated Entity96M100M60M57M65.6M75.7M
Retained Earnings Total Equity34.5B21.3B23.8B25.5B23.0B24.5B

Pair Trading with Bristol Myers

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bristol Stock

  0.69MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr

Moving against Bristol Stock

  0.7MMSI Merit Medical Systems Financial Report 24th of April 2024 PairCorr
  0.6MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.56KA Kineta Inc Report 29th of March 2024 PairCorr
  0.56VBIV VBI Vaccines Financial Report 20th of May 2024 PairCorr
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol-Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Bristol-Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.09)
Dividend Share
2.31
Earnings Share
3.86
Revenue Per Share
21.753
Quarterly Revenue Growth
0.006
The market value of Bristol-Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.